Elevance Health Price Target Lowered by Analysts

Truist Financial reduces price target on Elevance Health stock to $375 from $390

Apr. 13, 2026 at 1:37pm

Got story updates? Submit your updates here. ›

An extreme close-up of intricately connected gears, levers, and mechanical components in muted industrial tones, representing the complex financial infrastructure of a major health insurance company.The inner workings of a leading health insurance provider, a complex system of financial machinery that powers the delivery of coverage and benefits to millions.Indianapolis Today

Analysts at Truist Financial have lowered their price target on shares of Elevance Health (NYSE: ELV) from $390.00 to $375.00, while maintaining a 'buy' rating on the stock. The revised target price represents a potential upside of 21.18% from the stock's previous closing price.

Why it matters

Elevance Health is one of the largest health benefits companies in the United States, providing a wide range of insurance products and services. Analyst price target adjustments can influence investor sentiment and trading activity around the stock.

The details

In a research note issued on Monday, Truist Financial analysts cited various factors for the price target reduction, including the company's recent financial performance and market conditions. Despite the lower target, Truist Financial maintains a 'buy' recommendation on Elevance Health, suggesting the analysts still see upside potential in the stock.

  • Truist Financial analysts issued the updated price target on April 13, 2026.

The players

Elevance Health

A large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Elevance Health, formerly known as Anthem, is headquartered in Indianapolis, Indiana.

Truist Financial

A diversified financial services company that provides banking, insurance, and investment services. Truist Financial is one of the top research firms covering Elevance Health.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely monitoring Elevance Health's financial performance and any further updates from analysts regarding the company's outlook and valuation.

The takeaway

The price target reduction by Truist Financial reflects the ongoing challenges and uncertainties facing the healthcare industry, but the firm's 'buy' rating suggests it still sees long-term growth potential in Elevance Health's business.